CMC Biologics and IDT Biologika Collaborate on ADC Manufacturing
PTSM: Pharmaceutical Technology Sourcing and Management
Collaboration will provide for unified development and manufacture of antibody drug conjugates.
CMC Biologics, a clinical and commercial manufacturer of monoclonal antibodies and other therapeutic proteins, and IDT Biologika GmbH, a contract research, development, and manufacturing service provider of biologics for human and animal health, announced in February 2016 the formation of a strategic collaboration to manufacture antibody drug conjugates (ADCs).
CMC Biologics will perform process development and manufacture of the bulk monoclonal antibody. IDT Biologika will perform services from conjugation of the cytotoxic drug to the antibody substance through to the aseptic fill, finish, and packaging of the ADC final drug product. Initial services will become available to clients in April 2016.
The joint manufacturing efforts will provide speed, reliability, quality ADC manufacturing and a simplified supply chain, from DNA to finished drug product, for clinical trials and beyond through commercial manufacturing, the companies report in a press statement.
Sources:
IDT BiologikaCMC Biologics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
